<DOC>
	<DOCNO>NCT00431119</DOCNO>
	<brief_summary>To investigate safety efficacy oral methylprednisolone combine azathioprine mycophenolate mofetil treatment bullous pemphigoid .</brief_summary>
	<brief_title>Azathioprine Mycophenolate Mofetil Bullous Pemphigoid</brief_title>
	<detailed_description>This multicenter randomize , non-blinded clinical trial compare two parallel group patient bullous pemphigoid treat oral methylprednisolone combination either azathioprine mycophenolate mofetil . Patients randomly assign , irrespective severity disease , receive either 0.5 mg per kg body weight ( BW ) methylprednisolone ( Urbason® , Aventis Pharma , Bad Soden , Germany ) 2 mg per kg BW azathioprine sodium ( Imurek® , GlaxoSmithKline , Munich , Germany ) daily 0.5 mg per kg BW methylprednisolone daily 1,000 mg mycophenolate mofetil ( CellCept® provide Hoffmann-La Roche AG , Grenzach-Wyhlen , Germany ) , give twice daily ( 2 g/d ) . The initial dose maintain blister formation cease , crust well erosion disappear , re-epithelialization previous lesion start . The corticosteroid dose sequentially reduce 10 mg every two week dose 20 mg per day reach follow reduction 5 mg-steps every two week 10 mg per day . Afterwards , corticosteroid reduction perform 2.5 mg-steps every two week zero . After discontinuation corticosteroid azathioprine mycophenolate mofetil dos maintain initial dosage monotherapy additional 4 week . Subsequently , azathioprine reduce 0.5 mg per kg BW every four week dose 100 mg per day . Thereafter , azathioprine taper 25 mg-steps every four week discontinuation treatment . Mycophenolate mofetil reduce 500 mg/d-steps every four week 1,000 mg per day . From mycophenolate mofetil dosage decrease 250 mg-steps every four week discontinuation treatment .</detailed_description>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>clinical lesion suggestive bullous pemphigoid subepidermal blister upon histological analysis skin biopsy linear deposition IgG C3 along dermoepidermal junction deposition autoantibody blister roof upon splitskin analysis treatment oral topical corticosteroid , immunosuppressive drug previous four week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>bullous autoimmune disease</keyword>
	<keyword>bullous pemphigoid</keyword>
	<keyword>immunosuppressant</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>mycophenolate mofetil</keyword>
</DOC>